When good drugs go bad

被引：208
作者：
Giacomini, Kathleen M. [1 ]
Krauss, Ronald M.
Roden, Dan M.
Eichelbaum, Michel
Hayden, Michael R.
机构：
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
[2] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[4] Stuttgart Inst Klin Pharmakol, Stuttgart, Germany
[5] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[6] Univ Tokyo, Tokyo, Japan
来源：
NATURE | 2007年 / 446卷 / 7139期
关键词：
D O I：
10.1038/446975a
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
How can we best reduce the risk of severe adverse reactions to marketed drugs? An international group of scientists argues that a global research network is needed to identify genetically at-risk populations.
引用
收藏
页码：975 / 977
页数：3
相关论文
共 18 条
  • [1] Lazarou J(1998)undefined J. Am. Med. Assoc. 279 1200-1205
  • [2] Pomeranz BH(2006)undefined Drug Saf 29 161-168
  • [3] Corey PN(2006)undefined Toxicol. Mech. Meth. 16 89-99
  • [4] van der Hooft CS(1969)undefined Pharmacol. Rev. 21 73-103
  • [5] Huang SM(2006)undefined Ann. Intern. Med. 145 749-757
  • [6] Beutler E(2006)undefined Drug Saf 29 385-396
  • [7] Roden DM(2006)undefined Pharmacogenomics 7 633-638
  • [8] Hazell L(2003)undefined Toxicology 192 37-48
  • [9] Shakir SA(2006)undefined Annu. Rev. Med. 57 119-137
  • [10] Molokhia M(2004)undefined N. Engl. J. Med. 350 1013-1022
12